Saliva Irisin Level is Higher and Related With Interleukin 6 in Generalized Periodontitis
Condition: Inflammatory Response; Periodontitis
MeSH terms: Periodontitis
Study type: Interventional

Summary: 
      Irisin is novel adipomyokine known as a mediator of physical activity that produced mainly by
      skeletal muscle and adipose tissues. It is cleaved from the fibronectin type III
      domain-containing protein 5 (FDNC5), which is, in turn, induced by peroxisome
      proliferator-activated receptor-ɣ co-activator 1-α (PGC-1α). Several studies reported that
      irisin is related with pathogenesis of many diseases which are known to be associated with
      periodontal disease such as obesity, diabetes mellitus, rheumatoid arthritis, cardiovascular
      disease, nonalcoholic fatty liver disease and metabolic bone diseases. There are several
      studies those have reported that increased IL-6 levels are associated with progression and
      severity of periodontitis . Recently, it has been shown that irisin is expressed in human
      periodontal ligament cells (hPDL), dental pulp stem cells and osteoblasts. Also, a few
      studies revealed that irisin promotes growth, migration and matrix formation in hPDL cells
      and cementoblast differentiation. To the best our knowledge, there 's one study has been
      reported that the higher levels of irisin in saliva in patient with chronic periodontitis
    

Detailed description: 
      Twenty systemically healthy subjects with healthy periodontium and 20 patients with stage III
      grade B generalized periodontitis were enrolled for this cross-sectional study. The study was
      performed in accordance with the Helsinki Declaration of 1975, as revised in 2013. Before
      starting, the informed consent was obtained from all participants which was approved by the
      human subject's ethics board of Istanbul Medipol University's Faculty of Dentistry for use
      and access of human subjects in research.For all study subjects, the exclusion criteria were
      (1) use of contraceptive drugs; (2) use of antibiotics, anti-inflammatory drugs, or
      immunosuppressants in the last 3 months before the study; (3) alcohol consumption; (4)
      pregnancy or breastfeeding; (5) taking drugs that could cause side effects such as gingival
      hypertrophy or hyperplasia; and (6) any periodontal treatments in the 3 months prior to
      enrollment. All participants were systemically healthy and non-smokers (never smokers).The
      clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival
      recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded
      on periodontal charts in each patient .For the analysis of irisin and IL-6 specific ELISA
      Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum
      and saliva samples in accordance with the manufacturer's instructions. The minimum detectable
      doses of irisin and IL-6 for saliva with these assay kits were 1,28 and 13,22 pg/ml,
      respectively. For serum, minimum detectable irisin dose was 175,43 whereas IL-6 was 0,06
      pg/ml. All samples were run in duplicate, and values have been averaged.
    

Intervention name(s): Samples collection and ELISA analyses; Evaluating periodontal paramètres
Intervention type(s): Other; Diagnostic Test
Intervention description(s): The serum and unstimulated saliva samples were taken from all patients between 8:00 and 10:00 in the morning. Saliva samples were centrifuged at 10,000 rpm (10 min) whereas venous blood samples were centrifuged at 4000 rpm for 10 min.
For the analysis of irisin and IL-6 specific ELISA Kits (Elabscience, Houston, Texas, USA) were used to determine the molecules in both serum and saliva samples in accordance with the manufacturer's instructions. All samples were run in duplicate, and values have been averaged.; The clinical periodontal parameters (plaque index (PI), probing pocket depth (PD), gingival recession (GR), clinical attachment loss (CAL), and bleeding on probing (BOP)) were recorded on periodontal charts in each patient
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Diagnostic
Keywords: periodontitis; irisin